Albt2

Manufactured by Roche

The ALBT2 is a laboratory equipment product manufactured by Roche. It is designed for automated analysis of clinical samples. The core function of the ALBT2 is to perform high-throughput testing and processing of biological samples. The device is capable of handling a variety of sample types and conducting a range of analytical procedures.

Automatically generated - may contain errors

Lab products found in correlation

Cobas e601 module, by Roche (1 mentions) Cobas 6000, by Roche (1 mentions) Gluc3, by Roche (1 mentions) Ureal, by Roche (1 mentions) Crej2, by Roche (1 mentions) Combur 10 test, by Roche (1 mentions) Urea nitrogen colorimetric detection kit, by Thermo Fisher Scientific (1 mentions)

2 protocols using albt2

Standardized Biomarker Analysis in Fasting Blood Samples

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

From all subjects, blood samples were taken in the morning after an overnight fast. All analyses were conducted by COBAS 6000 (Roche Diagnostics, Risch-Rotkreuz, Switzerland) [19 (link),21 (link)]. Plasma insulin concentrations were measured on a COBAS e601 Module (Electrochemiluminescence Technology, Roche Diagnostics), and creatinine concentrations were measured by the kinetic colorimetric compensated Jaffé method using the Roche platform and the CREJ2–creatinine Jaffé Gen.2 assay (Roche Diagnostics, cod.0769282), which was standardized by isotope dilution mass spectrometry, traceable to National Institute of Standards and Technology creatinine standard reference material (SRM 914 and SRM 967) [29 (link)]. Urinary albumin was determined on 24 h urine collections by the turbidimetric immunoassay ALBT2 (Roche Diagnostics, cod.0767433). The remaining analytes were measured on a COBAS c 501 Clinical Chemistry Module (Photometric Technology, Roche Diagnostics) according to the manufacturer’s instructions.
Estimates of insulin resistance were calculated using the homeostasis model assessment of insulin resistance (HOMA-IR), defined by fasting insulin and fasting glucose [30 (link)].

Di Costanzo A., Pacifico L., D’Erasmo L., Polito L., Di Martino M., Perla F.M., Iezzi L., Chiesa C, & Arca M. (2019). Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight/Obese Children. International Journal of Molecular Sciences, 20(18), 4444.

+ Open protocol

+ Expand

Rodent Renal Function Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood was collected in-life from the saphenous vein and placed in heparin containing tubes.
Samples were centrifuged at 10,000 g for 10 minutes at 4 ºC to obtain plasma. Urine was collected on ice by housing the animals in a metabolic cage for 24 hrs. Water intake and urine volume were recorded. Initial urine analysis was conducted using a Combur 10 Test as per the manufacturer's instructions (Roche). In-depth analysis of protein, albumin, glucose, calcium, phosphate, urea and creatinine levels from plasma and urine were assayed on a c331 chemical analyser using commercially available kits, (TP2, ALBT2, GLUC3, CA2, PHOS2, UREAL and CREJ2; Roche). Blood Urea Nitrogen was assayed using Urea nitrogen colorimetric detection kit as per manufacturer's instructions (Thermo Scientific). The fractional excretion of phosphate (Fe ratio) was calculated using the following formula: FePi (%) = (24-h urine phosphate × serum creatinine)*100/(serum phosphate × 24-h urine creatinine).

Hollywood J.A., Kallingappa P.K., Cheung P.Y., Martis R.M., Sreebhavan S., 'Atiola R.D., Chatterjee A., Buckels E.J., Matthews B.G., Lewis P.M, & Davidson A.J. (2022). Cystinosin-deficient rats recapitulate the phenotype of nephropathic cystinosis. American journal of physiology. Renal physiology, 323(2).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!